MRNA vaccine takes on shingles: could it beat shingrix?

NCT ID NCT07285265

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to check safety and how well the body's immune system responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ABO1108 (mRNA vaccine for shingles)

What this could lead to

If successful, this could lead to a new, potentially more effective or easier-to-store shingles vaccine for older adults.

What could go wrong

This is an early Phase 1 trial with only 180 participants, so safety and immune response are still being tested. It may not prove effective or could have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chickenpox varicella zoster infection herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rongshui Miao Autonomous County Center for Disease Control and Prevention

    Liuzhou, Rongshui, China